[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Sanofi-Aventis S.A. ADR (SNY)

Sanofi-Aventis S.A. ADR (SNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 112,267,352
  • Shares Outstanding, K 2,439,004
  • Annual Sales, $ 52,854 M
  • Annual Income, $ 8,840 M
  • EBIT $ 12,044 M
  • EBITDA $ 18,468 M
  • 60-Month Beta 0.42
  • Price/Sales 2.27
  • Price/Cash Flow 6.50
  • Price/Book 1.31

Options Overview Details

View History
  • Implied Volatility 31.95% (+2.17%)
  • Historical Volatility 20.93%
  • IV Percentile 88%
  • IV Rank 69.46%
  • IV High 37.73% on 04/13/26
  • IV Low 18.81% on 06/09/25
  • Expected Move (DTE 15) 2.00 (4.34%)
  • Put/Call Vol Ratio 1.11
  • Today's Volume 2,463
  • Volume Avg (30-Day) 1,357
  • Put/Call OI Ratio 1.20
  • Today's Open Interest 52,895
  • Open Int (30-Day) 54,560
  • Expected Range 44.03 to 48.03

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $1.20
  • Number of Estimates 7
  • High Estimate $1.84
  • Low Estimate $1.05
  • Prior Year $0.90
  • Growth Rate Est. (year over year) +33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
45.42 +1.33%
on 04/29/26
48.60 -5.29%
on 04/23/26
-0.75 (-1.60%)
since 03/27/26
3-Month
43.32 +6.26%
on 03/18/26
49.42 -6.86%
on 02/11/26
-0.17 (-0.37%)
since 01/29/26
52-Week
43.32 +6.26%
on 03/18/26
55.73 -17.41%
on 05/02/25
-7.69 (-14.31%)
since 04/29/25

Most Recent Stories

More News
Giants Costco, Sanofi, and SAP Raise Dividends by Over 10%

Dividends are on the rise at Costco, Sanofi, and SAP, three of the world's largest companies with market capitalizations above $100 billion.

COST : 998.67 (+0.47%)
SAP : 170.10 (-1.95%)
WMT : 128.01 (+0.33%)
SNY : 46.03 (+0.17%)
Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)

Approval for children aged 2 to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID clinical trial program CSU is a chronic skin...

SAN.FP : 78.360 (+0.05%)
REGN : 686.36 (-6.21%)
SNY : 46.03 (+0.17%)
Sanofi's Pipeline Downgrades Suggest Thursday's Beat Won't Matter

Barchart Research What to Expect from SNY Earnings SNY Generated April 22, 2026 Current Price $46.90 EPS Estimate $$1.06 Consensus Rating Moderate Buy Average Move 3.92% Sanofi's Pipeline Downgrades Suggest...

SNY : 46.03 (+0.17%)
Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)

Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo ...

SAN.FP : 78.360 (+0.05%)
REGN : 686.36 (-6.21%)
SNY : 46.03 (+0.17%)
Sanofi announces leadership evolution in Specialty Care Business Unit

CAMBRIDGE, Mass. , Feb. 17, 2026 /PRNewswire/ -- Sanofi today announced the appointment of Manuela Buxo as Head of Specialty Care, effective March 1, 2026. Manuela will succeed Brian Foard,...

SAN : 11.98 (-0.75%)
SNY : 46.03 (+0.17%)
Flu Season's Here—This Dividend-Payer Controls the Shot Market

With flu season in full swing, drugmakers are hoping for a short-term tailwind after a lackluster 2025. Sanofi could be the winning ticket.

JNJ : 227.35 (-0.19%)
LLY : 851.21 (-2.61%)
ABBV : 203.89 (+3.14%)
GSK : 51.40 (-5.64%)
CSLLY : 22.2400 (-3.47%)
PFE : 26.26 (-0.83%)
SNY : 46.03 (+0.17%)
Dynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies Corporation - DVAX

NEW YORK and NEW ORLEANS , Dec. 30, 2025 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC ("KSF") are investigating...

DVAX : 15.50 (unch)
SNY : 46.03 (+0.17%)
Dynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies Corporation - DVAX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Dynavax Technologies Corporation...

DVAX : 15.50 (unch)
SNY : 46.03 (+0.17%)
Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo Dupixent...

SAN.FP : 78.360 (+0.05%)
REGN : 686.36 (-6.21%)
SNY : 46.03 (+0.17%)
Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are approximately 270,000 adults and adolescents aged 12 years...

SAN.FP : 78.360 (+0.05%)
REGN : 686.36 (-6.21%)
SNY : 46.03 (+0.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme,...

See More

Key Turning Points

3rd Resistance Point 47.07
2nd Resistance Point 46.62
1st Resistance Point 46.32
Last Price 46.03
1st Support Level 45.58
2nd Support Level 45.13
3rd Support Level 44.83

See More

52-Week High 55.73
Fibonacci 61.8% 50.99
Fibonacci 50% 49.53
Fibonacci 38.2% 48.06
Last Price 46.03
52-Week Low 43.32

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.